TABLE 3.
Antibiogram for Gram-negative bacterial isolatesa
| Gram-negative bacterium | Total no. of isolates | No. of isolates (%) susceptible to: |
|||||
|---|---|---|---|---|---|---|---|
| Cefepime | Ciprofloxacin | Gentamicin | Imipenem or meropenem | Piperacillin-tazobactam | IIAT | ||
| Achromobacter spp. | 12 | 3 (25) | 6 (50) | 0 (0) | 12 (100) | 9 (75) | 9 (75) |
| Acinetobacter spp. | 63 | 19 (30.2) | 15 (23.8) | 28 (44.4) | 31 (49.2) | 13 (20.6) | 44 (69.8) |
| Burkholderia spp. | 2 | 1 (50) | 1 (50) | 0 (0) | 1 (50) | 2 (100) | 1 (50) |
| Citrobacter spp. | 12 | 12 (100) | 9 (75) | 11 (91.7) | 12 (100) | 9 (75) | 3 (25) |
| Enterobacter spp. | 76 | 63 (82.9) | 57 (75) | 72 (94.7) | 70 (92.1) | 50 (65.8) | 23 (30.3) |
| Escherichia coli | 232 | 222 (95.7) | 182 (78.4) | 209 (90.1) | 230 (99.1) | 210 (90.5) | 41 (17.7) |
| Klebsiella spp. | 188 | 165 (87.8) | 158 (84.0) | 178 (94.7) | 183 (97.3) | 154 (81.9) | 44 (23.4) |
| Morganella morganii | 9 | 9 (100) | 8 (88.9) | 8 (88.9) | 9 (100) | 9 (100) | 0 (0) |
| Proteus spp. | 37 | 34 (91.9) | 25 (67.6) | 36 (97.3) | 36 (97.3) | 34 (91.9) | 7 (18.9) |
| Providencia spp. | 4 | 4 (100) | 3 (75) | 4 (100) | 3 (75) | 3 (75) | 0 (0) |
| Pseudomonas aeruginosa | 132 | 120 (90.9) | 95 (72) | 110 (83.3) | 116 (87.9) | 120 (90.9) | 41 (31.1) |
| Salmonella spp. | 6 | 5 (83.3) | 6 (100) | 6 (100) | 6 (100) | 6 (100) | 4 (66.7) |
| Serratia marcescens | 30 | 27 (90) | 26 (86.7) | 28 (93.3) | 28 (93.3) | 27 (90) | 14 (46.7) |
| Stenotrophomonas maltophilia | 20 | 6 (30) | 11 (55) | 8 (40) | 0 (0) | 7 (35) | 16 (80) |
| Cumulative | 823 | 690 (83.8) | 602 (73.1) | 698 (84.8) | 737 (89.6) | 653 (79.3) | 247 (30) |
a
Excludes two isolates of other Pseudomonas species isolated from blood cultures. For Escherichia coli, there were 7 ESBL producers; for Klebsiella spp., there were 16 ESBL producers. EBSL, extended-spectrum β-lactamase.